Therapeutic potential of agomelatine in epilepsy and epileptic complications

Medical Hypotheses

Volumn 82, Issue 1, 2014, Pages 105-110

  Vimala, P V ^a   Bhutada, P S ^a   Patel, F R ^a  

^a SINHGAD COLLEGE OF PHARMACY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

AGOMELATINE; MELATONIN 1 RECEPTOR; MELATONIN 2 RECEPTOR;

ANTICONVULSANT ACTIVITY; ANTIDEPRESSANT ACTIVITY; ANTIOXIDANT ACTIVITY; ANXIETY DISORDER; ARTICLE; CELL SURVIVAL; CIRCADIAN RHYTHM; COGNITIVE DEFECT; DEPRESSION; DRUG EFFECT; DRUG MECHANISM; EPILEPSY; FRONTAL CORTEX; HIPPOCAMPUS; HUMAN; MEMORY DISORDER; NERVOUS SYSTEM DEVELOPMENT; NEUROLOGICAL COMPLICATION; NEUROPROTECTION; NONHUMAN; SLEEP DISORDER; SLEEP QUALITY; TRANQUILIZING ACTIVITY;

ACETAMIDES; ANTIDEPRESSIVE AGENTS; CELL SURVIVAL; CIRCADIAN RHYTHM; DRUG DISCOVERY; EPILEPSY; HIPPOCAMPUS; HUMANS; MELATONIN; MODELS, BIOLOGICAL; NEUROGENESIS; RECEPTORS, MELATONIN; RECEPTORS, SEROTONIN;

EID: 84890888075     PISSN: 03069877     EISSN: 15322777     Source Type: Journal    
DOI: 10.1016/j.mehy.2013.11.017     Document Type: Article

References (86)

1. Strine T.W., Kobau R., Chapman D.P., Thurman D.J., Price P., Balluz L.S., et al. Psychological distress, comorbidities and health behaviors among U.S. adults with seizures: results from the 2002 National Health Interview Survey. Epilepsia 2002, 2005(46):1133-1139.
2. Majak K., Pitkaanen A. Do seizures cause irreversible cognitive damage? Evidence from animal studies. Epilepsy Behav 2004, 5:S35-S44.
3. Stafstrom C.E., Sutula T.P. Models of epilepsy in the developing and adult brain: implications for neuroprotection. Epilepsy Behav 2005, 7:S18-S24.
4. Mishra A., Goel R.K. Age dependent learning and memory deficit in pentylenetetrazole kindled mice. Eur J Pharmacol 2012, 674:315-320.
5. Kerr M.P., Turky A., Huber B. The psychosocial impact of epilepsy in adults with an intellectual disability. Epilepsy Behav 2009, 15:S26-S30.
6. Elixhausera A., Leidy N.K., Meador K., Means E., Willian M.K. The relationship between memory performance, perceived cognitive function, and mood in patients with epilepsy. Epilepsy Res 1999, 37:13-24.
7. Ponds R.W., Hendriks M. Cognitive rehabilitation of memory problems in patients with epilepsy. Seizure 2006, 15:267-273.
8. Motamedi G., Meador K. Epilepsy and cognition. Epilepsy Behav 2003, 4:S25-S38.
9. Agarwal N.B., Agarwal N.K., Mediratta P.K., Sharma K.K. Effect of lamotrigine, oxcarbazepine and topiramate on cognitive functions and oxidative stress in PTZ-kindled mice. Seizure 2011, 20:257-262.
10. McDonald B.C., Hummer T.A., David W., Dunn D.W. Functional MRI and structural MRI as tools for understanding comorbid conditions in children with epilepsy. Epilepsy Behav 2013, 26:295-302.
11. Sgobio C., Ghiglieri V., Costa C., et al. Hippocampal synaptic plasticity, memory, and epilepsy: effects of long-term valproic acid treatment. Biol Psychiatry 2010, 67:567-574.
12. Krishnakumar A., Nandhu M.S., Paulose C.S. Upregulation of 5-HT2C receptors in hippocampus of pilocarpine-induced epileptic rats: antagonism by Bacopa monnieri. Epilepsy Behav 2009, 16:225-230.
13. Menon B., Ramalingam K., Kumar R.V. Oxidative stress in patients with epilepsy is independent of antiepileptic drugs. Seizure 2012, 21:780-784.
14. Pohle W., Becker A., Grecksch G., Juhre A., Willenberg A. Piracetam prevents pentylenetetrazole kindling-induced neuronal loss and learning deficits. Seizure 1997, 6:467-474.
15. Gilliam F., Hecimovic H., Sheline Y. Psychiatric comorbidity, health, and function in epilepsy. Epilepsy Behav 2003, 4:S26-S30.
16. Mazarati A.M., Pineda E., Shin D., Tio D., Taylor A.N., Sankar R. Comorbidity between epilepsy and depression: role of hippocampal interleukin-1β. Neurobiol Dis 2010, 37:461-467.
17. Epps A.S., Weinshenker D. Rhythm and blues: animal models of epilepsy and depression comorbidity. Biochem Pharmacol 2013, 85:135-146.
18. Kanner A.M., Schachter S.C., Barry J.J., et al. Depression and epilepsy: epidemiologic and neurobiologic perspectives that may explain their high comorbid occurrence. Epilepsy Behav 2012, 24:156-168.
19. Jobe P.C. Common pathogenic mechanisms between depression and epilepsy: an experimental perspective. Epilepsy Behav 2003, 4:S14-24.
20. Kanner A.M. Depression in epilepsy: prevalence, clinical semiology, pathogenic mechanisms and treatment. Biol Psychiatry 2003, 54:388-398.
21. Kanner Andres M. Psychiatric issues in epilepsy: the complex relation of mood, anxiety disorders and epilepsy. Epilepsy Behav 2009, 15:83-87.
22. Sanacora G., Treccani G., Popoli M. Towards a glutamate hypothesis of depression: an emerging frontier of neuropsychopharmacology for mood disorders. Neuropharmacology 2012, 62:63-77.
23. Danzer S.C. Depression, stress, epilepsy and adult neurogenesis. Exp Neurol 2012, 233:22-32.
24. Schor N.K., Einat H. Circadian rhythms and depression: human psychopathology and animal models. Neuropharmacology 2012, 62:101-114.
25. Pizzol A.D., Martin K.C., Mattiello C.M., et al. Impact of the chronic use of benzodiazepines prescribed for seizure control on the anxiety levels of patients with epilepsy. Epilepsy Behav 2012, 23:373-376.
26. Beyenburg S., Mitchell A.J., Schmidt D., Elger C.E., Reuber M. Anxiety in patients with epilepsy: systematic review and suggestions for clinical management. Epilepsy Behav 2005, 7:161-171.
27. Cramer J.A., Brandenburg N., Xu X. Differentiating anxiety and depression symptoms in patients with partial epilepsy. Epilepsy Behav 2005, 6:563-569.
28. Yalyn O., Arman F., Erdogan F., Kula M. A comparison of the circadian rhythms and the levels of melatonin in patients with diurnal and nocturnal complex partial seizures. Epilepsy Behav 2006, 8:542-546.
29. Manni R., Galimberti C.A., Zucca C., Parietti L., Tartara A. Sleep patterns in patients with late onset partial epilepsy receiving chronic carbamazepine (CBZ) therapy. Epilepsy Res 1990, 7:72-76.
30. Ekizoglu E., Baykan B., Bebek N., Gurses C., Gokyigit A. Sleep characteristics of patients with epilepsy with pure sleep-related seizures. Epilepsy Behav 2011, 21:71-75.
31. Kothare S.V., Kaleyias J. Sleep and epilepsy in children and adolescents. Sleep Med 2010, 11:674-685.
32. Genkova-Papazova M., Lazarova-Bakarova M. Effects of nootropic drugs on pentylenetetrazole kindling in rats. Behav Pharmacol 1992, 3(Suppl. 1):142.
33. Costa-Lotufo L.V., Fonteles M.M.F., Lima I.S.P., et al. Attenuating effects of melatonin on pilocarpine-induced seizures in rats. Comp Biochem Physiol C Toxicol Pharmacol 2002, 131:521-529.
34. Borowicz K.K., Kaminski R., Gasior M., Kleinrok Z., Czuczwar S.J. Influence of melatonin upon the protective action of conventional antiepileptic drugs against maximal electroshock in mice. Eur Neuropsychopharmacol 1999, 9:185-190.
35. Lima E., Cabral F.R., Cavalheiro E.A., Naffah-Mazzacoratti Mda G., Amado D. Melatonin administration after pilocarpine-inducedstatus epilepticus: a new way to prevent or attenuate post lesion epilepsy?. Epilepsy Behav 2011, 20:607-612.
36. Firouz-Abadi N.Y., Tahsili-Fahadan P., Riazi K., Ghahremanib M.H., Dehpour A.R. Involvement of nitric oxide pathway in the acute anticonvulsant effect of melatonin in mice. Epilepsy Res 2006, 68:103-113.
37. Albertson T.E., Peterzson S.L., Stark L.G., Lakin M.L., Winter W.D. The anticonvulsant melatonin on kindled properties of seizures in rats. Neuropharmacology 1981, 20:61-66.
38. Moezi L., Shafaroodi H., Hojati A., Dehpour A.R. The interaction of melatonin and agmatine on pentylenetetrazole-induced seizure threshold in mice. Epilepsy Behav 2011, 22:200-206.
39. Tchekalarova J., Petkova Z., Pechlivanova D., et al. Prophylactic treatment with melatonin after status epilepticus: effects on epileptogenesis, neuronal damage and behavioral changes in a kainate model of temporal lobe epilepsy. Epilepsy Behav 2013, 27:174-187.
40. El-Azab M.F., Moustafa Y.M. Influence of calcium channel blockers on anticonvulsant and antinociceptive activities of valproic acid in pentylenetetrazole-kindled mice. Pharmacol Rep 2012, 64:305-314.
41. Bourin M., Mocaër E., Porsolt R. Antidepressant-like activity of S 20098 (agomelatine) in the forced swimming test in rodents: involvement of melatonin and serotonin receptors. J Psychiatry Neurosci 2004, 29:126-133.
42. AlAhmed S., Herbert J. Effect of agomelatine and its interaction with the daily corticosterone rhythm on progenitor cell proliferation in the dentate gyrus of the adult rat. Neuropharmacology 2010, 59:375-379.
43. Lopes C.M., Quera-Salva M.A., Guilleminault C. Non-REM sleep instability in patients with major depressive disorder: subjective improvement and improvement of non-REM sleep instability with treatment (Agomelatine). Sleep Med 2007, 9:33-41.
44. Anglade V.B., La-Rochelle C.D., Mocaer E., Seguin L. Memory facilitating effects of agomelatine in the novel object recognition memory paradigm in the rat. Pharmacol Biochem Behav 2011, 98:511-517.
45. Aguiar C.C.T., Almeida A.B., Araújo P.V.P., et al. Anticonvulsant effects of agomelatine in mice. Epilepsy Behav 2012, 24:324-328.
46. Yehuda S., Mostofsky D.I. Circadian effects of beta-endorphin, melatonin, DSIP and amphetamine on pentylenetetrazole- induced seizures. Peptides 1993, 14:203-205.
47. Slominski R.M., Reiter R.J., Loutsevitch N.S., Ostrom R.S., Slominski A.T. Melatonin membrane receptors in peripheral tissues: distribution and functions. Mol Cell Endocrinol 2012, 351:152-166.
48. Barbiero V.S., Zappettini S., Mocaer E., et al. The novel antidepressant agomelatine reduces release of glutamate and related presynaptic mechanisms in rat hippocampus. Eur Neuropsychopharmacol 2007, 17(Suppl. 4):S365.
49. Mallei M., Zappettini S., Musazzi L., et al. Agomelatine reduces glutamate release induced by acute stress, possible synergism between melatonin and 5HT2C properties. Eur Neuropsychopharmacol 2009, 19(Suppl. 3):S441-2.
50. Gressens P., Schwendimann L., Husson I., et al. Agomelatine, a melatonin receptor agonist with 5-HT2Creceptor antagonist properties, protects the developing murine white matter against excitotoxicity. Eur J Pharmacol 2008, 588:58-63.
51. Shin E.J., Jeong J.H., Chung Y.H. Role of oxidative stress in epileptic seizures. Neurochem Int 2011, 59:122-137.
52. Aguiar C.C., Almeida A.B., Araújo P.V., de Abreu R.N., Chaves E.M., Do Vale O.C., et al. Oxid Med Cell Longev 2012, 10.1155/2012/795259.
53. Dillioglugila M.O., Kir H.M., Demir C., et al. Effect of pentylenetetrazole and sound stimulation induced single and repeated convulsive seizures on the MDA, GSH and NO levels, and SOD activities in rat liver and kidney tissues. Brain Res Bull 2010, 8:356-359.
54. Cardinali D.P., Pagano E.S., Bernasconi P.A.S., Reynoso R., Scacchi P. Melatonin and mitochondrial dysfunction in the central nervous system. Horm Behav 2013, 63:322-330.
55. Banasr M., Soumier A., Hery M., Mocaer E., Daszuta A. Agomelatine, a new antidepressant, induces regional changes in hippocampal neurogenesis. Biol Psychiatry 2006, 59:1087-1096.
56. Fornaro M., Prestia D., Colicchio S., Perugi G. A systematic, updated review on the antidepressant agomelatine focusing on its melatonergic modulation. Curr Neuropharmacol 2010, 8:287-304.
57. Soumier A., Lortet S., Gabriel C., Mocaer E., Millan M.J., Daszuta A. Cellular and molecular mechanisms underlying increased adult hippocampal neurogenesis induced by agomelatine. Eur Neuropsychopharmacol 2008, 18(Suppl. 4):S350.
58. Dagyte G., Crescente I., Postema F., Seguin L., Gabriel C., Mocaer E., et al. Agomelatine reverses the decrease in hippocampal cell survival induced by chronic mild stress. Behav Brain Res 2011, 218:121-128.
59. Marinescu D., Udristoiu T., Mogoanta L., Udristoiu I., Pirici D. Neuroprotective potential of agomelatine for depression in Alzheimer's disease: animal model study. Eur Neuropsychopharmacol 2011, 21(Suppl. 3):S549.
60. The neuroprotective potentially of agomelatine - animal model study. Eur Psychiatry 2011, 26(Suppl. 1):1256.
61. Conboy L., Tanrikut C., Zoladz P.R., et al. The antidepressant agomelatine blocks the adverse effects of stress on memory and enables spatial learning to rapidly increase neural cell adhesion molecule (NCAM) expression in the hippocampus of rats. Int J Neuropsychopharmacol 2009, 3:329-341.
62. Bodinat C.D., Lemaitre G.B., Mocaer E., Renard P., Muñoz C., Millan M.J. Agomelatine, the first melatonergic antidepressant: discovery, characterization and development. Nat Rev Drug Discov 2010, 9:628-642.
63. Papp M., Gruca P., Mocaer E. Evidence for two components in the mechanism of action of S20098 (agomelatine) in a chronic mild stress animal model of depression. Eur Neuropsychopharmacol 2002, 12(Suppl. 3):194.
64. Demyttenaere K. Agomelatine: a narrative review. Eur Neuropsychopharmacol 2011, 21:S703-9.
65. Montgomery S.A. Major depressive disorders: clinical efficacy and tolerability of agomelatine, a new melatonergic agonist. Eur Neuropsychopharmacol 2006, 16:S633-8.
66. Srinivasan V., Zakaria R., Othman Z., Lauterbach E.C., Acuña-Castroviejo D. Agomelatine in depressive disorders: its novel mechanisms of action. J Neuropsychiatry Clin Neurosci 2012, 24:290-308.
67. Catena-Dell'Osso M., Marazziti D., Rotella F., Bellantuono C. Emerging targets for the pharmacological treatment of depression: focus on melatonergic system. Curr Med Chem 2012, 19:428-437.
68. Tuma J., Strubbe J.H., Mocaer E., Koolhaas J.M. Anxiolytic-like action of the antidepressant agomelatine (S 20098) after a social defeat requires the integrity of the SCN. Eur Neuropsychopharmacol 2005, 15:545-555.
69. Loiseau F., Le Bihan C., Hamon M., Thiébot M.H. Effects of melatonin and agomelatine in anxiety-related procedures in rats: interaction with diazepam. Eur Neuropsychopharmacol 2006, 16:417-428.
70. Rainer Q., Gabriel C., Mocaer E., Xia L., Hen R., Enhamre E., et al. Beneficial effects of chronic treatment with agomelatine on the anxiety- and depression-like state induced by corticosterone in C57BL/6NTAC mice. Eur Psychiatry 2010, 25(Suppl. 1):295.
71. Levitan M.N., Papelbaum M., Nardi A.E. A review of preliminary observations on agomelatine in the treatment of anxiety disorders. Exp Clin Psychopharmacol 2012, 6:504-509.
72. Stein D.J., Kennedy S.H. Efficacy of the novel antidepressant agomelatine for anxiety symptoms within depression. Eur Neuropsychopharmacol 2011, 21(Suppl. 3):S383D.
73. Stein D., Ahokas A., Allgulander C. Long-term treatment with agomelatine: prevention of relapse in patients with generalized anxiety disorder over 6 months. Eur Psychiatry 2011, 26(Suppl. 1):181.
74. Kennett G.A., Wood M.D., Bright F. SB 242084, a selective and brain penetrant 5-HT2C receptor antagonist. Neuropharrnacology 1997, 36:609-620.
75. Wichniak A., Wierzbicka A. The effects of antidepressants on sleep in depressed patients with particular reference to trazodone in comparison to agomelatine, amitriptyline, doxepin, mianserine and mirtazapine. Pol Merkur Lekarski 2011, 31:65-70.
76. Pandi-Perumal S.R., Zisapel N., Srinivasan V., Cardinali D.P. Melatonin and sleep in aging population. Exp Gerontol 2005, 40:911-925.
77. Racagni G. A new pharmacological step: the melatonergic approach. Eur Psychiatry 2007, 22(Suppl. 1):S91-2.
78. Kennedy S.H. Agomelatine antidepressant: advantages over sertraline and venlafaxine in "clinical effectiveness". Eur Neuropsychopharmacol 2009, 19(Suppl. 3):S419-20.
79. Kasper S., Laigle L., Baylé F. Superior antidepressant efficacy of agomelatine versus sertraline: a randomised, double-blind study. Eur Neuropsychopharmacol 2008, 18(Suppl. 4):S336-7.
80. Guilleminault C. Efficacy of agomelatine versus venlafaxine on subjective sleep of patients with major depressive disorder. Eur Neuropsychopharmacol 2005, 15(Suppl. 3):S419-20.
81. Kupfer D.J. Depression and associated sleep disturbances: patient benefits with agomelatine. Eur Neuropsychopharmacol 2006, 16:S639-643.
82. Lam R. The benefits of agomelatine beyond antidepressant efficacy: impact on sleep. Eur Neuropsychopharmacol 2005, 15(Suppl. 3):S660.
83. Corruble E., Bélaidi C., Goodwin G.M. Agomelatine versus escitalopram in major depressive disorders: a randomized double-blind, long term study focusing on sleep satisfaction and emotional blunting. Eur Psychiatry 2011, 26(Suppl. 1):619.
84. Quera-Salva M.A., Vanier B., Chapotot F. Effect of agomelatine on the sleep EEG in patients with major depressive disorder (MMD). Eur Neuropsychopharmacol 2005, 15(Suppl. 3):S435-6.
85. Pandi-Perumal S.R., Moscovitch A., Srinivasan V., Spence D.W., Cardinali D.P., Brown G.M. Bidirectional communication between sleep and circadian rhythms and its implications for depression: lessons from agomelatine. Prog Neurobiol 2009, 88:264-271.
86. Nassiri-Asla M., Mortazavi S.R., Samiee-Rad F., Zangivand A.A., Safdari F., Saroukhani S., et al. The effects of rutin on the development of pentylenetetrazole kindling and memory retrieval in rats. Epilepsy Behav 2010, 18:50-53.